Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q3 2014 Earnings Presentation
14 slides from Bactiguard Holding Ab's earnings presentation, Nov 14, 2014
Slide 1: Innovating for the healthcare needs of today and tomorrow
Innovating for the healthcare needs of today and tomorrow Q3 presentation, 14 November 2014
Slide 2: The global health scare: Reality
The global health scare Reality The reality we have to adress ”Multi resistant bacteria is a greater threat to mankind than climate change …” Professor Hans Rosling, Karolinska Institutet ”Antimicrobial resistance is so serious that it threatens modern medicine. A post-antibiotic era in which common
Slide 3: The global health scare: Sweden
The global health scare Sweden Patients with Healthcare Associated Infections 12% 10% 8% 6% 4% 2% 0% VT 08 HT 08 VT 09 HT 09 VT 10 HT 10 VT11 HT11 VT12 HT12 VT13 HT13 VT14 Totalsumma Source Sveriges Kommuner och Landsting (SKL), Sept 2014 2014-11-13 3
Slide 4: Bactiguard Infection Protection
Targeting the most common HAIs and risks Bactiguard Infection Protection ...explaining the rationale behind the products in Occurrence of HAI US (all hospital types) the Bactiguard portfolio Other Urinary tract BIP Foley 17% 32% Surgical site 22% 14% 15% Blood stream BIP ETT Respiratory tract Hospit
Slide 5: Business expansion
Business expansion Phase 1 Phase 2 Phase 3 Steady revenue from license Further development of BIP Expand geographically through business Portfolio distributors Phase 4 Start development of BIP Signed contracts with Product approvals in all relevant portfolio distributors in 34 countries
Slide 6: Market expansion
Market expansion Bactiguard is present in 51 geographical markets, with production facilities in Sweden and Malaysia Bactiguard presence Countries with distribution agreements Direct sales Bard territory* Production facility Portfolio roll-out Markets Markets Markets with with product approval deliv
Slide 7: Highlights in the third quarter
Highlights in the third quarter • Somewhat slow quarter • Negotiations with new government in Iraq • Strengthening our sales and marketing organization • Preparations and sales training in new markets – South America, Middle East and India • European market presence expanded to Portugal • Market ent
Slide 8: Highlights
Financial overview Highlights Third Quarter (July-September 2014) • Revenues of MSEK 28.1, minus 14% compared to 2013 (major delivery to Iraq in Q3 2013 affects comparison) • EBITDA of MSEK 2.2 (4.7), margin 8% (14%) Nine-month (January-September 2014) • Revenues of MSEK 93.8, plus 13% compared to 2
Slide 9: Supplied products
Financial overview Supplied products • 12,000 BIP products supplied in Q3 compared to 62,000 during Q3 2013. • During the first nine months of 2014 71,000 BIP products supplied compared to 86,000 corresponding period 2013. 2014-11-13 9
Slide 10: Revenue streams
Financial overview Revenue streams Three revenue streams in the income statement License BIP portfolio Bard license deal BIP Foley BIP ETT BIP CVC (sales since 1995) 1 2 3 License Territorial fee BIP revenue • From a product perspective Bactiguard has two lines of business, Licenses and the BIP port
Slide 11: Income distribution
Financial overview Income distribution Q3 Q3 Q1-Q3 MSEK 2014 2013 2014 License revenues 24,3 21,3 69,6 Territorial fees 0,6 0,0 17,0 BIP products 0,5 10,4 2,1 Other revenue 2,6 0,8 5,1 Total revenues 28,1 32,5 93,8 2014-11-13 11
Slide 12: Key figures
Financial overview Key figures Jul-Sep Jul-Sep Jan-Sep • EBITDA (Q3) of MSEK 2.2, Key figures 2014 2013 2014 8% EBITDA margin. Revenues, SEKm 28,1 32,5 93,8 • EBITDA adjusted (Q1-Q3) EBITDA, SEKm 2,2 4,7 14,2 MSEK 17.2, 18% EBITDA EBITDA margin, % 8% 14% 15% margin EBITDA*, SEKm 2,2 4,7 17,2 • Net p
Slide 13: Financial flexibility and strength
Financial overview Financial flexibility and strength Q2 Share issue of MSEK 20 to M2 Asset Management AB in April Set off issue of MSEK 222.5 in June Share issue of MSEK 240 in connection with IPO Q3 • Repurchase of bonds, nominal value MSEK 18.5 • Equity ratio of 62 % 30 Sep • Net debt of MS
Slide 14: Concluding remarks
Concluding remarks • Healthcare associated infections and multiresistant bacteria - some of the greatest challenges of our time • Bactiguard has an efficient, safe and well proven solution for infection control • Through the IPO we achieved a solid financial position and flexibility • Stable platfor